4 | ASO Visual Abstract: CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/ nab-Paclitaxel for Patients with Operable Pancreatic Cancer. (Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S) Ann Surg Oncol 2023 May;30(5):3022 |
4 | CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. (Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S) Ann Surg Oncol 2023 May;30(5):3013-3021 |
2 | Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial. (Hall WA, Evans DB, Tsai S) JAMA Oncol 2023 Feb 01;9(2):275-276 |
3 | A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma. (Saif A, Verbus E, Erickson B, Kamgar M, Tsai S, Evans D, Hernandez JM, Hall WA) Ann Surg Oncol 2023 Feb;30(2):688-690 |
1 | Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy. (Hammad AY, Hodges JC, AlMasri S, Paniccia A, Lee KK, Bahary N, Singhi AD, Ellsworth SG, Aldakkak M, Evans DB, Tsai S, Zureikat A) JAMA Surg 2023 Jan 01;158(1):55-62 |
3 | Predicting Neoadjuvant Treatment Response in Rectal Cancer Using Machine Learning: Evaluation of MRI-Based Radiomic and Clinical Models. (Peterson KJ, Simpson MT, Drezdzon MK, Szabo A, Ausman RA, Nencka AS, Knechtges PM, Peterson CY, Ludwig KA, Ridolfi TJ) J Gastrointest Surg 2023 Jan;27(1):122-130 1 Citation |
1 | Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. (Cobb AN, Diao K, Teshome M, Lucci A, Ueno NT, Stauder M, Layman RM, Kuerer HM, Woodward WA, Sun SX) Ann Surg Oncol 2022 Oct;29(10):6381-6392 2 Citations |
1 | Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium. (Kelly KN, Macedo FI, Seaton M, Wilson G, Hammill C, Martin RC, Maduekwe UN, Kim HJ, Maithel SK, Abbott DE, Ahmad SA, Kooby DA, Merchant NB, Datta J) Ann Surg Oncol 2022 Sep;29(9):6004-6012 3 Citations |
1 | Outcomes of Mixed Pathologic Response in Patients with Multiple Colorectal Liver Metastases Treated with Neoadjuvant Chemotherapy and Liver Resection. (Mason MC, Krasnodebski M, Hester CA, Kothari AN, Barker C, Nishioka Y, Chiang YJ, Newhook TE, Tzeng CD, Chun YS, Vauthey JN, Tran Cao HS) Ann Surg Oncol 2022 Aug;29(8):5156-5164 1 Citation |
2 | Evolving Concepts Regarding Radiation Therapy for Pancreatic Cancer. (Hall WA, Erickson B, Crane CH) Surg Oncol Clin N Am 2021 Oct;30(4):719-730 1 Citation |
1 | GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. (Thaker PH, Bradley WH, Leath CA 3rd, Gunderson Jackson C, Borys N, Anwer K, Musso L, Matsuzaki J, Bshara W, Odunsi K, Alvarez RD) Clin Cancer Res 2021 Oct 15;27(20):5536-5545 5 Citations |
2 | Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline. (Salerno KE, Alektiar KM, Baldini EH, Bedi M, Bishop AJ, Bradfield L, Chung P, DeLaney TF, Folpe A, Kane JM, Li XA, Petersen I, Powell J, Stolten M, Thorpe S, Trent JC, Voermans M, Guadagnolo BA) Pract Radiat Oncol 2021;11(5):339-351 28 Citations |
1 | Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. (Rahma OE, Yothers G, Hong TS, Russell MM, You YN, Parker W, Jacobs SA, Colangelo LH, Lucas PC, Gollub MJ, Hall WA, Kachnic LA, Vijayvergia N, O'Rourke MA, Faller BA, Valicenti RK, Schefter TE, George S, Kainthla R, Stella PJ, Sigurdson E, Wolmark N, George TJ) JAMA Oncol 2021 Aug 01;7(8):1225-1230 45 Citations |
1 | HER-2/neu-positive breast cancer neoadjuvant chemotherapy response after implementation of 2018 ASCO/CAP focused update. (Wang L, Asirvatham JR, Ma Y, Reisenbichler ES, Jorns JM) Breast J 2021 Aug;27(8):631-637 3 Citations |
2 | Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer-Medical college of Wisconsin perspective. (Ward EP, Evans DB, Tsai S) J Surg Oncol 2021 May;123(6):1405-1413 2 Citations |
2 | Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer. (Mahadevan A, Moningi S, Grimm J, Li XA, Forster KM, Palta M, Prior P, Goodman KA, Narang A, Heron DE, Lo SS, Urbanic J, Herman JM) Int J Radiat Oncol Biol Phys 2021 May 01;110(1):206-216 20 Citations |
4 | Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. (Mora J, Krepline AN, Aldakkak M, Christians KK, George B, Hall WA, Erickson BA, Kulkarni N, Evans DB, Tsai S) Am J Surg 2021 Jul;222(1):10-17 24 Citations |
1 | Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. (Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson WC, Hartman HE, Kishan AU, Mehra R, Kaffenberger S, Morgan TM, Reichert ZR, Alumkal JJ, Michalski J, Lee WR, Pisansky TM, Feng FY, Shipley W, Sandler HM, Schipper MJ, Roach M 3rd, Sun Y, Lawton CAF) J Clin Oncol 2021 Jan 10;39(2):136-144 42 Citations |
4 | Total Neoadjuvant Therapy for Operable Pancreatic Cancer. (Kim RY, Christians KK, Aldakkak M, Clarke CN, George B, Kamgar M, Khan AH, Kulkarni N, Hall WA, Erickson BA, Evans DB, Tsai S) Ann Surg Oncol 2021 Apr;28(4):2246-2256 21 Citations |
1 | Is Breast Magnetic Resonance Imaging an Accurate Predictor of Nodal Status After Neoadjuvant Chemotherapy? (Cortina CS, Gottschalk N, Kulkarni SA, Karst I) J Surg Res 2021 Jan;257:412-418 4 Citations |
1 | Commentary: Surgery for locally advanced pancreatic cancer after neoadjuvant therapy. (Evans DB) Surgery 2021 May;169(5):1032-1033 2 Citations |
1 | The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned From SWOG S1505. (Evans DB) Ann Surg 2020 Sep 01;272(3):487 8 Citations |
8 | Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. (Barnes CA, Aldakkak M, Christians KK, Clarke CN, Dua K, George B, Ritch PS, Kamgar M, Hall WA, Kulkarni N, Erickson BA, Evans DB, Tsai S) Surgery 2020 Sep;168(3):440-447 11 Citations |
1 | Early stage triple negative breast cancer: Management and future directions. (Chaudhary LN) Semin Oncol 2020 Aug;47(4):201-208 18 Citations |
2 | Neoadjuvant radiation improves margin-negative resection rates in extremity sarcoma but not survival. (Shelby RD, Suarez-Kelly LP, Yu PY, Hughes TM, Ethun CG, Tran TB, Poultsides G, King DM, Bedi M, Mogal H, Clarke C, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Krasnick BA, Fields RC, Pollock RE, Howard JH, Cardona K, Grignol V) J Surg Oncol 2020 Jun;121(8):1249-1258 6 Citations |
3 | Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma. (Rowan DJ, Hartley CP, Aldakkak M, Christians KK, Evans DB, Tsai S, Hagen CE) Ann Diagn Pathol 2020 Jun;46:151485 3 Citations |
3 | Is a Nomogram Able to Predict Postoperative Wound Complications in Localized Soft-tissue Sarcomas of the Extremity? (Bedi M, Ethun CG, Charlson J, Tran TB, Poultsides G, Grignol V, Howard JH, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Cullinan D, Fields RC, Cardona K, King DM) Clin Orthop Relat Res 2020 Mar;478(3):550-559 9 Citations |
1 | Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria. (Kardashian A, Florman SS, Haydel B, Ruiz RM, Klintmalm GB, Lee DD, Taner CB, Aucejo F, Tevar AD, Humar A, Verna EC, Halazun KJ, Chapman WC, Vachharajani N, Hoteit M, Levine MH, Nguyen MH, Melcher ML, Langnas AN, Carney CA, Mobley C, Ghobrial M, Amundsen B, Markmann JF, Sudan DL, Jones CM, Berumen J, Hemming AW, Hong JC, Kim J, Zimmerman MA, Nydam TL, Rana A, Kueht ML, Fishbein TM, Markovic D, Busuttil RW, Agopian VG) Hepatology 2020 Dec;72(6):2014-2028 45 Citations |
3 | A high mitotic score in breast cancer after neoadjuvant chemotherapy is predictive of outcome and associated with a distinct morphology. (Arispe Angulo KR, Jawa Z, Visotcky A, Majidi SS, Chitambar CR, Jorns JM) Histopathology 2020 Apr;76(5):661-670 |
3 | Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? (Krepline AN, Bliss L, Geurts J, Akinola I, Christians KK, George B, Ritch PS, Hall WA, Erickson BA, Evans DB, Tsai S) J Gastrointest Surg 2020 Feb;24(2):235-242 6 Citations |
5 | Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. (Jariwalla NR, Khan AH, Dua K, Christians KK, Clarke CN, Aldakkak M, George B, Tutton S, Rilling W, Erickson B, Evans DB, Tsai S) Ann Surg Oncol 2019 Dec;26(13):4515-4521 6 Citations |
1 | Correlation of CT texture changes with treatment response during radiation therapy for esophageal cancer: An exploratory study. (Yan Z, Zhang J, Long H, Sun X, Li D, Tang T, Li XA, Hui W) PLoS One 2019;14(9):e0223140 4 Citations |
2 | Goals of Treatment Sequencing for Localized Pancreatic Cancer. (Evans DB, Kamgar M, Tsai S) Ann Surg Oncol 2019 Nov;26(12):3815-3819 5 Citations |
4 | Use of Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Rectal Cancer. (Hu KY, Simpson MT, Blank JJ, Szabo A, Eastwood D, Ludwig KA, Peterson CY, Ridolfi TJ) J Surg Res 2019 Nov;243:447-452 10 Citations |
1 | Treatment of Hepatocellular Carcinoma: Time for a Paradigm Shift? (White SB) Radiology 2019 Sep;292(3):760-761 1 Citation |
1 | Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative. (Zaidi MY, Ethun CG, Tran TB, Poultsides G, Grignol VP, Howard JH, Bedi M, Mogal H, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Krasnick B, Fields RC, Oskouei S, Reimer N, Monson D, Maithel SK, Cardona K) Ann Surg Oncol 2019 Oct;26(11):3542-3549 16 Citations |
1 | Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. (Macedo FI, Ryon E, Maithel SK, Lee RM, Kooby DA, Fields RC, Hawkins WG, Williams G, Maduekwe U, Kim HJ, Ahmad SA, Patel SH, Abbott DE, Schwartz P, Weber SM, Scoggins CR, Martin RCG, Dudeja V, Franceschi D, Livingstone AS, Merchant NB) Ann Surg 2019 Sep;270(3):400-413 91 Citations |
1 | Covered and uncovered biliary metal stents provide similar relief of biliary obstruction during neoadjuvant therapy in pancreatic cancer: a randomized trial. (Seo DW, Sherman S, Dua KS, Slivka A, Roy A, Costamagna G, Deviere J, Peetermans J, Rousseau M, Nakai Y, Isayama H, Kozarek R, Biliary SEMS During Neoadjuvant Therapy Study Group) Gastrointest Endosc 2019 Oct;90(4):602-612.e4 46 Citations |
8 | Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. (Barnes CA, Chavez MI, Tsai S, Aldakkak M, George B, Ritch PS, Dua K, Clarke CN, Tolat P, Hagen C, Hall WA, Erickson BA, Evans DB, Christians KK) Surgery 2019 Sep;166(3):277-285 35 Citations |
3 | The role of radiation therapy and margin width in localized soft-tissue sarcoma: Analysis from the US Sarcoma Collaborative. (Gannon NP, King DM, Ethun CG, Charlson J, Tran TB, Poultsides G, Grignol V, Howard JH, Tseng J, Roggin KK, Votanopoulos K, Krasnick B, Fields RC, Cardona K, Bedi M) J Surg Oncol 2019 Sep;120(3):325-331 14 Citations |
4 | Downstaging Locally Advanced Cholangiocarcinoma Pre-Liver Transplantation: A Prospective Pilot Study. (Wong M, Kim J, George B, Eriksen C, Pearson T, Robbins J, Zimmerman MA, Hong JC) J Surg Res 2019 Oct;242:23-30 17 Citations |
1 | Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials. (Hallemeier CL, Zhang P, Pisansky TM, Hanks GE, McGowan DG, Roach M 3rd, Zeitzer KL, Firat SY, Husain SM, D'Souza DP, Souhami L, Parliament MB, Rosenthal SA, Lukka HR, Rotman M, Horwitz EM, Miles EF, Paulus R, Sandler HM) Int J Radiat Oncol Biol Phys 2019 Aug 01;104(5):1057-1065 7 Citations |
1 | Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium. (DiNorcia J, Florman SS, Haydel B, Tabrizian P, Ruiz RM, Klintmalm GB, Senguttuvan S, Lee DD, Taner CB, Verna EC, Halazun KJ, Hoteit M, Levine MH, Chapman WC, Vachharajani N, Aucejo F, Nguyen MH, Melcher ML, Tevar AD, Humar A, Mobley C, Ghobrial M, Nydam TL, Amundsen B, Markmann JF, Berumen J, Hemming AW, Langnas AN, Carney CA, Sudan DL, Hong JC, Kim J, Zimmerman MA, Rana A, Kueht ML, Jones CM, Fishbein TM, Markovic D, Busuttil RW, Agopian VG) Ann Surg 2020 Apr;271(4):616-624 43 Citations |
2 | Pathologic necrosis following neoadjuvant radiotherapy or chemoradiotherapy is prognostic of poor survival in soft tissue sarcoma. (Gannon NP, Stemm MH, King DM, Bedi M) J Cancer Res Clin Oncol 2019 May;145(5):1321-1330 14 Citations |
3 | Does Vacuum-assisted Closure Reduce the Risk of Wound Complications in Patients With Lower Extremity Sarcomas Treated With Preoperative Radiation? (Bedi M, King DM, DeVries J, Hackbarth DA, Neilson JC) Clin Orthop Relat Res 2019 Apr;477(4):768-774 19 Citations |
1 | Call for improved design and reporting in soft tissue sarcoma studies: A systematic review and meta-analysis of chemotherapy and survival outcomes in resectable STS. (Istl AC, Ruck JM, Morris CD, Levin AS, Meyer CF, Johnston FM) J Surg Oncol 2019 Jun;119(7):824-835 11 Citations |
2 | Patient selection in studies evaluating esophageal stents during neoadjuvant therapy. (Smith ZL, Dua KS) Gastrointest Endosc 2019 Jan;89(1):205-206 2 Citations |
1 | Contemporary analysis of complications associated with biliary stents during neoadjuvant therapy for pancreatic adenocarcinoma. (Kim BJ, Prakash L, Narula N, Davis CH, Kim MP, Aloia TA, Vauthey JN, Lee JE, Katz MH, Tzeng CD) HPB (Oxford) 2019 Jun;21(6):662-668 7 Citations |
1 | State of the art: Rehabilitation of speech and swallowing after total laryngectomy. (Zenga J, Goldsmith T, Bunting G, Deschler DG) Oral Oncol 2018 Nov;86:38-47 37 Citations |
6 | Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. (Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin M, Hagen C, Hall WA, Erickson BA, Evans DB) Ann Surg 2020 Apr;271(4):740-747 96 Citations |
3 | Management of the axilla after neo-adjuvant chemotherapy for breast cancer: Sentinel node biopsy and radiotherapy considerations. (Currey A, Patten CR, Bergom C, Wilson JF, Kong AL) Breast J 2018 Nov;24(6):902-910 6 Citations |
1 | The association of socioeconomic status with receipt of neoadjuvant chemotherapy. (Neuner JM, Kong A, Blaes A, Riley D, Chrischilles E, Smallwood A, Lizarraga I, Schroeder M) Breast Cancer Res Treat 2019 Jan;173(1):179-188 9 Citations |
6 | A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. (Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, Mackinnon AC, Tolat P, Ahmad SA, Hall WA, Erickson BA, Evans DB) Ann Surg 2018 Oct;268(4):610-619 52 Citations |
1 | Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. (Retseck J, Nasr A, Lin Y, Lin H, Mendiratta P, Butterfield LH, Tarhini AA) J Transl Med 2018 Jul 04;16(1):184 29 Citations |
6 | Postoperative Day 1 Glucose May Be Associated With Wound Complications in Sarcomas Treated With Preoperative Radiation. (Bedi M, King DM, Mendez C, Slawski B, Charlson JA, Hackbarth DA, Neilson JC) Clin Orthop Relat Res 2018 Mar;476(3):580-586 1 Citation |
4 | Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. (Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN) JAMA Oncol 2018 Mar 01;4(3):343-350 100 Citations |
1 | Considerations for sentinel lymph node biopsy in breast cancer patients with biopsy proven axillary disease prior to neoadjuvant treatment. (Qu LT, Peters S, Cobb AN, Godellas CV, Perez CB, Vaince FT) Am J Surg 2018 Mar;215(3):530-533 6 Citations |
7 | Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis. (Bhalla M, Aldakkak M, Kulkarni NM, O'Connor SD, Griffin MO Jr, Christians KK, Evans DB, Tsai S, Tolat PP) Abdom Radiol (NY) 2018 Feb;43(2):351-363 11 Citations |
1 | Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy. (Delitto D, George TJ Jr, Loftus TJ, Qiu P, Chang GJ, Allegra CJ, Hall WA, Hughes SJ, Tan SA, Shaw CM, Iqbal A) J Natl Cancer Inst 2018 May 01;110(5):460-466 14 Citations |
1 | Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy? (Chaudhary LN, Wilkinson KH, Kong A) Surg Oncol Clin N Am 2018 Jan;27(1):141-153 72 Citations |
3 | Self-Expanding Metal Stents Improve Swallowing and Maintain Nutrition During Neoadjuvant Therapy for Esophageal Cancer. (Smith ZL, Gonzaga JE, Haasler GB, Gore EM, Dua KS) Dig Dis Sci 2017 Jun;62(6):1647-1656 6 Citations |
1 | Accuracy and Thoroughness of Treatment Summaries Provided as Part of Survivorship Care Plans Prepared by Two Cancer Centers. (Tevaarwerk AJ, Hocking WG, Zeal JL, Gribble M, Seaborne L, Buhr KA, Wisinski KB, Burkard ME, Wiegmann DA, Sesto ME) J Oncol Pract 2017 May;13(5):e486-e495 11 Citations |
5 | Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer. (Rajamanickam ES, Christians KK, Aldakkak M, Krepline AN, Ritch PS, George B, Erickson BA, Foley WD, Aburajab M, Evans DB, Tsai S) J Gastrointest Surg 2017 Mar;21(3):496-505 6 Citations |
1 | Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. (Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE) J Gastrointest Surg 2017 Jan;21(1):164-174 104 Citations |
6 | Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated? (Krepline AN, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Evans DB, Tsai S) J Surg Oncol 2016 Oct;114(5):581-586 18 Citations |
4 | Evolution of the Management of Resectable Pancreatic Cancer. (Tsai S, Erickson BA, Dua K, Ritch PS, Tolat P, Evans DB) J Oncol Pract 2016 Sep;12(9):772-8 23 Citations |
1 | Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. (de Geus SW, Evans DB, Bliss LA, Eskander MF, Smith JK, Wolff RA, Miksad RA, Weinstein MC, Tseng JF) Eur J Surg Oncol 2016 Oct;42(10):1552-60 44 Citations |
2 | Therapeutic Advances in Localized Pancreatic Cancer. (Tsai S, Evans DB) JAMA Surg 2016 Sep 01;151(9):862-8 47 Citations |
4 | Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. (Asare EA, Evans DB, Erickson BA, Aburajab M, Tolat P, Tsai S) J Surg Oncol 2016 Sep;114(3):291-5 15 Citations |
1 | Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. (Guancial EA, Kilari D, Xiao GQ, Abu-Farsakh SH, Baran A, Messing EM, Kim ES) PLoS One 2016;11(5):e0155503 5 Citations |
2 | Neoadjuvant radiotherapy for retroperitoneal sarcoma: A systematic review. (Cheng H, Miura JT, Lalehzari M, Rajeev R, Donahue AE, Bedi M, Gamblin TC, Turaga KK, Johnston FM) J Surg Oncol 2016 May;113(6):628-34 20 Citations |
2 | Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients. (Kilari D, Iczkowski KA, Pandya C, Robin AJ, Messing EM, Guancial E, Kim ES) Anticancer Res 2016 Feb;36(2):495-501 38 Citations |
6 | Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. (Christians KK, Heimler JW, George B, Ritch PS, Erickson BA, Johnston F, Tolat PP, Foley WD, Evans DB, Tsai S) Surgery 2016 Mar;159(3):893-900 97 Citations |
2 | Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy. (Nudelman KN, McDonald BC, Wang Y, Smith DJ, West JD, O'Neill DP, Zanville NR, Champion VL, Schneider BP, Saykin AJ) J Clin Oncol 2016 Mar 01;34(7):677-83 35 Citations |
4 | Biopsies in the Community Lead to Postoperative Complications in Soft Tissue Sarcomas. (Bedi M, King DM, Hackbarth DA, Charlson JA, Baynes K, Neilson JC) Orthopedics 2015 Sep;38(9):e753-9 4 Citations |
5 | Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. (Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Evans DB, Tsai S) HPB (Oxford) 2015 Oct;17(10):942-52 47 Citations |
5 | Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. (Miura JT, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Oshima K, Christians KK, Evans DB, Tsai S) Surgery 2015 Dec;158(6):1545-55 27 Citations |
3 | Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy. (Evans DB, George B, Tsai S) Ann Surg Oncol 2015 Oct;22(11):3409-13 64 Citations |
1 | Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. (Rodrigues G, Choy H, Bradley J, Rosenzweig KE, Bogart J, Curran WJ Jr, Gore E, Langer C, Louie AV, Lutz S, Machtay M, Puri V, Werner-Wasik M, Videtic GMM) Pract Radiat Oncol 2015;5(3):149-155 40 Citations |
1 | Adherence to Guidelines for Adjuvant Imatinib Therapy for GIST: A Multi-institutional Analysis. (Bischof DA, Dodson R, Jimenez MC, Behman R, Cocieru A, Blazer DG 3rd, Fisher SB, Squires MH 3rd, Kooby DA, Maithel SK, Groeschl RT, Gamblin TC, Bauer TW, Karanicolas PJ, Law C, Quereshy FA, Pawlik TM) J Gastrointest Surg 2015 Jun;19(6):1022-8 12 Citations |
2 | Significant Reduction of Late Toxicities in Patients With Extremity Sarcoma Treated With Image-Guided Radiation Therapy to a Reduced Target Volume: Results of Radiation Therapy Oncology Group RTOG-0630 Trial. (Wang D, Zhang Q, Eisenberg BL, Kane JM, Li XA, Lucas D, Petersen IA, DeLaney TF, Freeman CR, Finkelstein SE, Hitchcock YJ, Bedi M, Singh AK, Dundas G, Kirsch DG) J Clin Oncol 2015 Jul 10;33(20):2231-8 165 Citations |
2 | Neoadjuvant therapy for localized pancreatic cancer: support is growing? (Evans DB, Ritch PS, Erickson BA) Ann Surg 2015 Jan;261(1):18-20 18 Citations |
1 | Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. (Cooper AB, Slack R, Fogelman D, Holmes HM, Petzel M, Parker N, Balachandran A, Garg N, Ngo-Huang A, Varadhachary G, Evans DB, Lee JE, Aloia T, Conrad C, Vauthey JN, Fleming JB, Katz MH) Ann Surg Oncol 2015 Jul;22(7):2416-23 111 Citations |
2 | Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. (Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2015 Jan 01;91(1):116-23 29 Citations |
6 | Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. (Kharofa J, Tsai S, Kelly T, Wood C, George B, Ritch P, Wiebe L, Christians K, Evans DB, Erickson B) Radiother Oncol 2014 Oct;113(1):41-6 42 Citations |
6 | Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. (Jayakrishnan TT, Nadeem H, Groeschl RT, George B, Thomas JP, Ritch PS, Christians KK, Tsai S, Evans DB, Pappas SG, Gamblin TC, Turaga KK) HPB (Oxford) 2015 Feb;17(2):131-9 15 Citations |
1 | Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. (Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH) Lung Cancer 2014 Jul;85(1):88-93 58 Citations |
1 | Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy. (Bednarski BK, Habra MA, Phan A, Milton DR, Wood C, Vauthey N, Evans DB, Katz MH, Ng CS, Perrier ND, Lee JE, Grubbs EG) World J Surg 2014 Jun;38(6):1318-27 39 Citations |
1 | Polymeric micelles for apoptosis-targeted optical imaging of cancer and intraoperative surgical guidance. (Cho H, Cho CS, Indig GL, Lavasanifar A, Vakili MR, Kwon GS) PLoS One 2014;9(2):e89968 14 Citations |
7 | Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? (Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B) Oncologist 2014 Mar;19(3):266-74 160 Citations |
1 | Neoadjuvant chemotherapy for localized pancreatic cancer: too little or too long? (White RR, Evans DB) Ann Surg Oncol 2014 May;21(5):1508-9 1 Citation |
1 | Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. (Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey JN, Aloia TA, Fleming JB, Katz MH) J Gastrointest Surg 2014 Jan;18(1):16-24; discussion 24-5 152 Citations |
1 | Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. (Tran Cao HS, Balachandran A, Wang H, Nogueras-González GM, Bailey CE, Lee JE, Pisters PW, Evans DB, Varadhachary G, Crane CH, Aloia TA, Vauthey JN, Fleming JB, Katz MH) J Gastrointest Surg 2014 Feb;18(2):269-78; discussion 278 87 Citations |
1 | ACR Appropriateness Criteria® management of locoregionally advanced squamous cell carcinoma of the vulva. (Expert Panel on Radiation Oncology-Gynecology, Kidd E, Moore D, Varia MA, Gaffney DK, Elshaikh MA, Erickson B, Jhingran A, Lee LJ, Mayr NA, Puthawala AA, Rao GG, Small W Jr, Wahl AO, Wolfson AH, Yashar CM, Yuh W, Cardenes HR) Am J Clin Oncol 2013 Aug;36(4):415-22 17 Citations |
5 | Prognostic variables in patients with primary soft tissue sarcoma of the extremity and trunk treated with neoadjuvant radiotherapy or neoadjuvant sequential chemoradiotherapy. (Bedi M, King DM, Shivakoti M, Wang T, Zambrano EV, Charlson J, Hackbarth D, Neilson J, Whitfield R, Wang D) Radiat Oncol 2013 Mar 14;8:60 21 Citations |
1 | The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. (Abbott DE, Tzeng CW, Merkow RP, Cantor SB, Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary GR, Abbruzzese JL, Wolff RA, Lee JE, Evans DB, Fleming JB) Ann Surg Oncol 2013 Dec;20 Suppl 3:S500-8 55 Citations |
3 | Novel multimodality treatment sequencing for extrahepatic (mid and distal) cholangiocarcinoma. (Turaga KK, Tsai S, Wiebe LA, Evans DB, Gamblin TC) Ann Surg Oncol 2013 Apr;20(4):1230-9 9 Citations |
1 | Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. (Suntharalingam M, Paulus R, Edelman MJ, Krasna M, Burrows W, Gore E, Wilson LD, Choy H) Int J Radiat Oncol Biol Phys 2012 Oct 01;84(2):456-63 83 Citations |
1 | Loco-regional therapy in patients with Milan Criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: an outcome analysis. (Sourianarayanane A, El-Gazzaz G, Sanabria JR, Menon KV, Quintini C, Hashimoto K, Kelly D, Eghtesad B, Miller C, Fung J, Aucejo F) HPB (Oxford) 2012 May;14(5):325-32 11 Citations |
1 | Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study. (Aadam AA, Evans DB, Khan A, Oh Y, Dua K) Gastrointest Endosc 2012 Jul;76(1):67-75 81 Citations |
1 | Ex vivo evaluation of preoperatively treated rectal cancer specimens of patients undergoing radical resection. (de la Fuente SG, Ludwig KA, Tyler DS, Mantyh CR) Ann Surg Oncol 2012 Jun;19(6):1954-8 2 Citations |
1 | Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. (Wang J, Estrella JS, Peng L, Rashid A, Varadhachary GR, Wang H, Lee JE, Pisters PW, Vauthey JN, Katz MH, Gomez HF, Evans DB, Abbruzzese JL, Fleming JB, Wang H) Cancer 2012 Aug 01;118(15):3801-11 56 Citations |
2 | Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. (Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2012 Mar 15;82(4):1367-75 60 Citations |
1 | Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. (Estrella JS, Rashid A, Fleming JB, Katz MH, Lee JE, Wolf RA, Varadhachary GR, Pisters PW, Abdalla EK, Vauthey JN, Wang H, Gomez HF, Evans DB, Abbruzzese JL, Wang H) Cancer 2012 Jan 01;118(1):268-77 65 Citations |
1 | Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. (Hong JC, Jones CM, Duffy JP, Petrowsky H, Farmer DG, French S, Finn R, Durazo FA, Saab S, Tong MJ, Hiatt JR, Busuttil RW) Arch Surg 2011 Jun;146(6):683-9 151 Citations |
1 | Impact of neoadjuvant chemotherapy on breast reconstruction. (Hu YY, Weeks CM, In H, Dodgion CM, Golshan M, Chun YS, Hassett MJ, Corso KA, Gu X, Lipsitz SR, Greenberg CC) Cancer 2011 Jul 01;117(13):2833-41 40 Citations |
2 | Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy. (Evans DB, Erickson BA, Ritch P) Ann Surg Oncol 2010 Nov;17(11):2803-5 57 Citations |
1 | International preoperative rectal cancer management: staging, neoadjuvant treatment, and impact of multidisciplinary teams. (Augestad KM, Lindsetmo RO, Stulberg J, Reynolds H, Senagore A, Champagne B, Heriot AG, Leblanc F, Delaney CP, International Rectal Cancer Study Group (IRCSG)) World J Surg 2010 Nov;34(11):2689-700 80 Citations |
2 | Portal vein resection. (Christians KK, Lal A, Pappas S, Quebbeman E, Evans DB) Surg Clin North Am 2010 Apr;90(2):309-22 36 Citations |
2 | Management of borderline resectable pancreatic cancer. (Lal A, Christians K, Evans DB) Surg Oncol Clin N Am 2010 Apr;19(2):359-70 9 Citations |
1 | Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. (Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang H, Crane CH, Lee JH, Tamm EP, Abbruzzese JL, Evans DB) Ann Surg Oncol 2010 Jul;17(7):1794-801 124 Citations |
1 | Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. (Dong X, Jiao L, Li Y, Evans DB, Wang H, Hess KR, Abbruzzese JL, Li D) J Clin Oncol 2009 Apr 01;27(10):1592-9 43 Citations |
1 | Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. (Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB) Ann Surg Oncol 2009 Apr;16(4):836-47 395 Citations |
1 | Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. (Bass R, Perry B, Langenstroer P, Thrasher JB, Dennis KL, Tawfik O, Holzbeierlein J) J Urol 2009 Feb;181(2):615-9; discussion 619-20 24 Citations |
1 | Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. (Chen J, Li D, Killary AM, Sen S, Amos CI, Evans DB, Abbruzzese JL, Frazier ML) Ann Surg Oncol 2009 Feb;16(2):431-9 40 Citations |
1 | Neoadjuvant chemoradiation for rectal cancer reduces lymph node harvest in proctectomy specimens. (de la Fuente SG, Manson RJ, Ludwig KA, Mantyh CR) J Gastrointest Surg 2009 Feb;13(2):269-74 53 Citations |
1 | Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. (Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB) J Clin Oncol 2008 Jul 20;26(21):3487-95 410 Citations |
1 | Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. (Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA) J Clin Oncol 2008 Jul 20;26(21):3496-502 644 Citations |
1 | Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. (Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF) J Am Coll Surg 2008 May;206(5):833-46; discussion 846-8 660 Citations |
1 | Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413. (Taussky D, Bae K, Bahary JP, Roach M 3rd, Lawton CA, Shipley WU, Sandler HM) Urology 2008 Nov;72(5):1125-9 11 Citations |
1 | Future chemoradiation strategies in pancreatic cancer. (Crane CH, Varadhachary G, Pisters PW, Evans DB, Wolff RA) Semin Oncol 2007 Aug;34(4):335-46 28 Citations |
1 | Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. (Atallah E, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H) Blood 2007 Nov 15;110(10):3547-51 67 Citations |
1 | An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. (Lawton CA, DeSilvio M, Roach M 3rd, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR Jr) Int J Radiat Oncol Biol Phys 2007 Nov 01;69(3):646-55 394 Citations |
1 | Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. (Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M) Pediatr Blood Cancer 2007 Aug;49(2):196-8 26 Citations |
1 | Surgical patterns of care in operable lung carcinoma treated with radiation. (Chang JY, Moughan J, Johnstone DW, Komaki R, Goldberg M, Langer CJ, Beadle BM, Owen J, Movsas B) J Thorac Oncol 2006 Jul;1(6):526-31 4 Citations |
1 | Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). (Gonzalez RJ, Buzdar AU, Fraser Symmans W, Yen TW, Broglio KR, Lucci A, Esteva FJ, Yin G, Kuerer HM) Breast J 2007;13(1):72-5 24 Citations |
1 | The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. (Crane CH, Varadhachary G, Wolff RA, Pisters PW, Evans DB) Best Pract Res Clin Gastroenterol 2006 Apr;20(2):365-82 43 Citations |
1 | Preoperative chemoradiation for pancreatic cancer. (Evans DB) Semin Oncol 2005 Dec;32(6 Suppl 9):S25-9 13 Citations |
1 | Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. (Wright JD, Dehdashti F, Herzog TJ, Mutch DG, Huettner PC, Rader JS, Gibb RK, Powell MA, Gao F, Siegel BA, Grigsby PW) Cancer 2005 Dec 01;104(11):2484-91 152 Citations |
1 | The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. (Iczkowski KA, Qiu J, Qian J, Somerville MC, Rittmaster RS, Andriole GL, Bostwick DG) Urology 2005 Jan;65(1):76-82 66 Citations |
1 | Neoadjuvant therapy for resectable pancreatic cancer. (Raut CP, Evans DB, Crane CH, Pisters PW, Wolff RA) Surg Oncol Clin N Am 2004 Oct;13(4):639-61, ix 53 Citations |
1 | Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. (Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut M, Ford J, Curran W, Phan S, Smith JA, Miller RA, Renschler MF) J Clin Oncol 2002 Aug 15;20(16):3445-53 134 Citations |
1 | Therapeutic options and treatment of muscle invasive bladder cancer. (O'Connor RC, Alsikafi NF, Steinberg GD) Expert Rev Anticancer Ther 2001 Dec;1(4):511-22 7 Citations |
1 | Multimodality management of localized pancreatic cancer. (Wayne JD, Wolff RA, Pisters PW, Evans DB) Cancer J 2001;7 Suppl 1:S35-46 12 Citations |
1 | Preoperative chemoradiation therapy for pancreatic cancer. (Evans DB, Pisters PW) Surg Clin North Am 2001 Jun;81(3):709-13 3 Citations |
1 | Neoadjuvant strategies for pancreatic cancer. (Evans DB, Wolff RA, Crane CH) Oncology (Williston Park) 2001 Jun;15(6):727-37; discussion 741-4, 747 13 Citations |
1 | Preoperative chemoradiation for resectable and locally advanced adenocarcinoma of the pancreas. (Evans DB) J Gastrointest Surg 2001;5(1):2-5 18 Citations |
1 | Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. (Pisters PW, Hudec WA, Lee JE, Raijman I, Lahoti S, Janjan NA, Rich TA, Crane CH, Lenzi R, Wolff RA, Abbruzzese JL, Evans DB) J Clin Oncol 2000 Feb;18(4):860-7 80 Citations |
1 | Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. (Bold RJ, Charnsangavej C, Cleary KR, Jennings M, Madray A, Leach SD, Abbruzzese JL, Pisters PW, Lee JE, Evans DB) J Gastrointest Surg 1999;3(3):233-43 114 Citations |
1 | Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. (Breslin TM, Janjan NA, Lee JE, Pisters PW, Wolff RA, Abbruzzese JL, Evans DB) Front Biosci 1998 Nov 01;3:E193-203 20 Citations |